Deposition, imaging, and clearance: what remains to be done?
Deposition and clearance studies are used during product development and in fundamental research. These studies mostly involve radionuclide imaging, but pharmacokinetic methods are also used to assess the amount of drug absorbed through the lungs, which is closely related to lung deposition. Radionu...
Published in: | Journal of Aerosol Medicine and Pulmonary Drug Delivery |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2012
|
Subjects: | |
Online Access: | http://hdl.handle.net/2381/19096 https://doi.org/10.1089/jamp.2010.0839 |
id |
ftleicester:oai:lra.le.ac.uk:2381/19096 |
---|---|
record_format |
openpolar |
spelling |
ftleicester:oai:lra.le.ac.uk:2381/19096 2023-05-15T16:52:12+02:00 Deposition, imaging, and clearance: what remains to be done? Scheuch, G Bennett, W Borgström, L Clark, A Dalby, R Dolovich, M Fleming, J Gehr, P Gonda, I O'Callaghan, C Taylor, G Newman, S 2012-10-24T09:06:20Z metadata http://hdl.handle.net/2381/19096 https://doi.org/10.1089/jamp.2010.0839 eng eng J AEROSOL MED PULM DRUG DELIV, 2010, 23 Suppl 2, pp. S39-S57 http://hdl.handle.net/2381/19096 doi:10.1089/jamp.2010.0839 1941-2703 PubMed http://www.ncbi.nlm.nih.gov/pubmed/ Administration Inhalation Aerosols Animals Drug Delivery Systems Drug Design Humans Lung Nebulizers and Vaporizers Pharmaceutical Preparations Radionuclide Imaging Research Tissue Distribution Journal Article 2012 ftleicester https://doi.org/10.1089/jamp.2010.0839 2019-03-22T20:16:51Z Deposition and clearance studies are used during product development and in fundamental research. These studies mostly involve radionuclide imaging, but pharmacokinetic methods are also used to assess the amount of drug absorbed through the lungs, which is closely related to lung deposition. Radionuclide imaging may be two-dimensional (gamma scintigraphy or planar imaging), or three-dimensional (single photon emission computed tomography and positron emission tomography). In October 2009, a group of scientists met at the "Thousand Years of Pharmaceutical Aerosols" conference in Reykjavik, Iceland, to discuss future research in key areas of pulmonary drug delivery. This article reports the session on "Deposition, imaging and clearance." The objective was partly to review our current understanding, but more importantly to assess "what remains to be done?" A need to standardize methodology and provide a regulatory framework by which data from radionuclide imaging methods could be compared between centers and used in the drug approval process was recognized. There is also a requirement for novel radiolabeling methods that are more representative of production processes for dry powder inhalers and pressurized metered dose inhalers. A need was identified for studies to aid our understanding of the relationship between clinical effects and regional deposition patterns of inhaled drugs. A robust methodology to assess clearance from small conducting airways should be developed, as a potential biomarker for therapies in cystic fibrosis and other diseases. The mechanisms by which inhaled nanoparticles are removed from the lungs, and the factors on which their removal depends, require further investigation. Last, and by no means least, we need a better understanding of patient-related factors, including how to reduce the variability in pulmonary drug delivery, in order to improve the precision of deposition and clearance measurements. 44204 Article in Journal/Newspaper Iceland University of Leicester: Leicester Research Archive (LRA) Journal of Aerosol Medicine and Pulmonary Drug Delivery 23 S2 S-39 S-57 |
institution |
Open Polar |
collection |
University of Leicester: Leicester Research Archive (LRA) |
op_collection_id |
ftleicester |
language |
English |
topic |
Administration Inhalation Aerosols Animals Drug Delivery Systems Drug Design Humans Lung Nebulizers and Vaporizers Pharmaceutical Preparations Radionuclide Imaging Research Tissue Distribution |
spellingShingle |
Administration Inhalation Aerosols Animals Drug Delivery Systems Drug Design Humans Lung Nebulizers and Vaporizers Pharmaceutical Preparations Radionuclide Imaging Research Tissue Distribution Scheuch, G Bennett, W Borgström, L Clark, A Dalby, R Dolovich, M Fleming, J Gehr, P Gonda, I O'Callaghan, C Taylor, G Newman, S Deposition, imaging, and clearance: what remains to be done? |
topic_facet |
Administration Inhalation Aerosols Animals Drug Delivery Systems Drug Design Humans Lung Nebulizers and Vaporizers Pharmaceutical Preparations Radionuclide Imaging Research Tissue Distribution |
description |
Deposition and clearance studies are used during product development and in fundamental research. These studies mostly involve radionuclide imaging, but pharmacokinetic methods are also used to assess the amount of drug absorbed through the lungs, which is closely related to lung deposition. Radionuclide imaging may be two-dimensional (gamma scintigraphy or planar imaging), or three-dimensional (single photon emission computed tomography and positron emission tomography). In October 2009, a group of scientists met at the "Thousand Years of Pharmaceutical Aerosols" conference in Reykjavik, Iceland, to discuss future research in key areas of pulmonary drug delivery. This article reports the session on "Deposition, imaging and clearance." The objective was partly to review our current understanding, but more importantly to assess "what remains to be done?" A need to standardize methodology and provide a regulatory framework by which data from radionuclide imaging methods could be compared between centers and used in the drug approval process was recognized. There is also a requirement for novel radiolabeling methods that are more representative of production processes for dry powder inhalers and pressurized metered dose inhalers. A need was identified for studies to aid our understanding of the relationship between clinical effects and regional deposition patterns of inhaled drugs. A robust methodology to assess clearance from small conducting airways should be developed, as a potential biomarker for therapies in cystic fibrosis and other diseases. The mechanisms by which inhaled nanoparticles are removed from the lungs, and the factors on which their removal depends, require further investigation. Last, and by no means least, we need a better understanding of patient-related factors, including how to reduce the variability in pulmonary drug delivery, in order to improve the precision of deposition and clearance measurements. 44204 |
format |
Article in Journal/Newspaper |
author |
Scheuch, G Bennett, W Borgström, L Clark, A Dalby, R Dolovich, M Fleming, J Gehr, P Gonda, I O'Callaghan, C Taylor, G Newman, S |
author_facet |
Scheuch, G Bennett, W Borgström, L Clark, A Dalby, R Dolovich, M Fleming, J Gehr, P Gonda, I O'Callaghan, C Taylor, G Newman, S |
author_sort |
Scheuch, G |
title |
Deposition, imaging, and clearance: what remains to be done? |
title_short |
Deposition, imaging, and clearance: what remains to be done? |
title_full |
Deposition, imaging, and clearance: what remains to be done? |
title_fullStr |
Deposition, imaging, and clearance: what remains to be done? |
title_full_unstemmed |
Deposition, imaging, and clearance: what remains to be done? |
title_sort |
deposition, imaging, and clearance: what remains to be done? |
publishDate |
2012 |
url |
http://hdl.handle.net/2381/19096 https://doi.org/10.1089/jamp.2010.0839 |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
PubMed http://www.ncbi.nlm.nih.gov/pubmed/ |
op_relation |
J AEROSOL MED PULM DRUG DELIV, 2010, 23 Suppl 2, pp. S39-S57 http://hdl.handle.net/2381/19096 doi:10.1089/jamp.2010.0839 1941-2703 |
op_doi |
https://doi.org/10.1089/jamp.2010.0839 |
container_title |
Journal of Aerosol Medicine and Pulmonary Drug Delivery |
container_volume |
23 |
container_issue |
S2 |
container_start_page |
S-39 |
op_container_end_page |
S-57 |
_version_ |
1766042361091063808 |